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Abstract:
Purpose: Combinations of tyrosine kinase inhibitors (TKIs) with gemcitabine have been attempted with little added benefit to patients. We hypothesized that TKIs designed to bind to ATP binding pockets of growth factor receptors also bind to transporter proteins that recognize nucleosides.
Experimental design: TKI inhibition of uridine transport was studied with recombinant human (h) equilibrative (E) and concentrative (C) nucleoside transporters (hENTs, hCNTs) produced individually in yeast. TKIs effects on uridine transport, gemcitabine accumulation, regulation of hENT1 activity and cell viability in the presence or absence of gemcitabine were evaluated in human pancreatic and lung cancer cell lines. erlotinib, gefitinib or vandetanib for 24 h reduced hENT1 activity which was reversed by subsequent incubation in drug free media for 24 h. Greater cytotoxicity was observed when gemcitabine was administered prior to erlotinib, gefitinib or vandetanib than when administered together and synergy, evaluated using the CalcuSyn Software, was observed in three cell lines resulting in combination indices under 0.6 at 50% reduction of cell growth.
Results: Erlotinib, gefitinib and vandetanib inhibited [

Conclusions:
Vandetanib inhibited hENT1, hENT2, hCNT1, hCNT2 and hCNT3 whereas erlotinib inhibited hENT1 and hCNT3 and gefitinib inhibited hENT1 and hCNT1. The potential for reduced accumulation of nucleoside chemotherapy drugs in tumor tissues due to inhibition of hENTs and/or hCNTs by TKIs indicates that pharmacokinetic properties of these agents must be considered when scheduling TKIs and nucleoside chemotherapy in combination.
Introduction
The Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor (TKI) erlotinib for maintenance of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and more recently as a first-line treatment in NSCLC patients with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. Similarly gefitinib has been approved for EGFR mutation positive NSCLC in more than 80 countries worldwide. It showed impressive single agent activity and received accelerated FDA approval based on early phase II studies pending definitive randomized studies (1).
However, in one of the pivotal randomized studies, gefitinib was combined at doses of 250 or 500 mg/day with gemcitabine/cisplatin with expectations that the two gefitinib combinations would be superior to gemcitabine/cisplatin alone in NSCLC but there were no statistical differences between placebo and treatment arms in terms of progression free survival (PFS) (2) .
In a phase II trial in advanced urothelial carcinoma patients treated with gemcitabine/cisplatin and concurrent gefitinib, response rates were not significantly different from gemcitabine/cisplatin alone (3) . Gemcitabine and gefitinib were evaluated in advanced pancreatic cancer patients (4) and response rates were similar to those observed in a pivotal phase III study in patients with locally advanced or metastatic pancreatic cancer with gemcitabine or gemcitabine and erlotinib with median survival of 5.9 to 6.2 months. Addition of gefitinib to gemcitabine in a different phase II trial in urothelial carcinoma patients did not result in increased response rates compared to the control arm of gemcitabine/cisplatin (5) . Vandetanib was initially evaluated in advanced NSCLC patients and the combination of vandetanib with gemcitabine/cisplatin was not tolerated in these patients (6) . Combining conventional cytotoxic drugs with novel agents that target key signaling pathways that control cancer cell survival, proliferation and/or invasion should be a promising approach, and several clinical trials of TKIs (2-6) suggest that there may be unfavorable interactions between TKIs and nucleoside chemotherapy drugs. Although literature reports suggest that TKIs interfere with uptake of nucleoside chemotherapy drugs (7) (8) (9) (10) , detailed studies of TKI effects on individual human nucleoside transporters (hNTs) or a theory to explain why TKIs inhibit hNTs are lacking. Transporters for physiologic nucleosides and nucleoside analogs include human equilibrative nucleoside transporters 1-4 (hENT1-4) and human concentrative nucleoside transporters (hCNT1-3). Detailed summaries of hNTs' roles in transport of nucleoside drugs can be found in recent reviews (11, 12) .
We hypothesized that poor clinical outcomes of combining erlotinib, gefitinib or vandetanib with nucleoside chemotherapy drugs (e.g., gemcitabine) were due to TKI inhibition of hNTs, resulting in lowered intracellular accumulation of nucleoside drug metabolites and reduced treatment efficacy. To study potential interactions between TKIs and hNTs, we investigated TKI inhibition of uridine transport in yeast cells producing each of recombinant hNTs individually and TKI effects on uridine uptake, gemcitabine accumulation and cytotoxicity in one pancreatic adenocarcinoma cell line AsPC-1 and three human NSCLC cells that differ in their epidermal growth factor receptor (EGFR) and KRAS mutation status -i.e., A549 (EGFR wild-type and KRAS mutant), H292 (EGFR wild-type and KRAS wild-type), and H1975 (EGFR L858R, T790M mutation and wild-type KRAS).
Research. 
Cell culture:
Human lung cancer cell lines A549, H292, and H1975 and the human pancreatic cancer cell line AsPC-1 were obtained from American Type Culture Collection (Manassas, VA). Cell lines were sent to DDC Medical (Fairfield, OH) to verify their authenticity and mycoplasma status. Results showed that cell lines were 100% matched to the ATCC panel of markers and were free of mycoplasma. Cells were maintained in Roswell Park Memorial Institute 1640 medium supplemented with 10% FBS, 2 mM L-glutamine and 10% glucose. All cultures were kept at 37°C in 5% CO 2 /95% air and sub-cultured at two to three day intervals to maintain exponential growth. Transport and cytotoxicity experiments were conducted with cells in exponential growth phase.
Choice of TKI concentrations to be studied
Plasma concentrations of gefitinib, erlotinib, and vandetanib are 0.4, 2.5 and 2.0 μM respectively (13) (14) (15) were 42 fold higher than plasma concentrations (15) . Similarly vandetanib tumor concentrations were 30 fold higher in tumor tissues than in plasma (16). Given structural similarities among the three TKIs, we expected similar concentrating effects to be seen with erlotinib and assumed that gefitinib, erlotinib, and vandetanib concentrations were likely to be considerably higher in tumor tissues than in plasma (15, 16) . We therefore studied TKI concentrations up to 100 μM in cell lines and 300 μM in yeast model systems.
Uridine transport in Saccharomyces cerevisiae:
Saccharomyces cerevisiae yeast were separately transformed with plasmids (pYPhENT1, pYPhENT2, pYPhCNT1, pYPhCNT2, or pYPhCNT3) encoding hNTs (hENT1, hENT2, hCNT1, hCNT2, or hCNT3, respectively) as described elsewhere (17, 18). Uptake of 1 µM Concentration-effect curves were subjected to nonlinear regression analysis using Prism software (version 4.03; GraphPad Software Inc., San Diego, CA) to obtain the concentration of test compound that inhibited uridine uptake by 50% relative to that of untreated cells (IC 50 Research. 
Cytotoxicity assays:
Dojindo Cell Counting Kit-8 (CCK-8) was used to quantify drug induced cytotoxicity. Cells were seeded in 96-well plates and allowed to attach for 24 h. Cells were then exposed to graded Table 1, where it is evident that hENT1 was inhibited by all three TKIs, whereas hENT2 and hCNT1/2/3 were inhibited to different extents by the three TKIs. Vandetanib inhibited hENT1, hENT2, hCNT1, hCNT2 and hCNT3 whereas erlotinib inhibited hENT1 and hCNT3 and gefitinib inhibited hENT1 and hCNT1.
To assess TKI inhibition of hNT activity in A549, H292, H1975 and AsPC-1 cells, we first established the type of hNT activities present by conducting [ Results indicated a decrease in hENT1-mediated activity after exposure to erlotinib, gefitinib or vandetanib in all cell lines tested. This decrease in NT activity was reversed after culturing cells in drug free media for 24 h. To determine if reduced NT activity was due to altered protein levels, we used SAHENTA-FITC (a non-permeable fluorescent hENT1 probe) to measure the abundance of hENT1 sites on cell surfaces as described earlier (20). A549 cells were treated with erlotinib, gefitinib or vandetanib for 24 h and, after recovery in drug free media for another 24 h, were stained with 100 nM SAHENTA-FITC and processed as described in the Materials and Methods section. Figure 3E 
permeation is important for gemcitabine toxicity. Similar experiments conducted with gefitinib and vandetanib ( Figure 4B ) in A549 cells showed no effects of dilazep on gefitinib or vandetanib cytotoxicity. Erlotinib, gefitinib and vandetanib toxicities (0-100 µM) were assessed over 72 h in all four cell lines and IC 50 values (mean ± S.E) are summarized in Table 2 .
In vitro combination studies with gemcitabine and erlotinib, gefitinib or vandetanib
Results described in Figure 3B Table 2 . These results indicated that the sequence, gemcitabine followed by TKIs, was synergistic whereas the sequence TKI followed by gemcitabine or simultaneous treatment ranged from additive to antagonistic thus supporting our In this study we showed that hENT or hCNT mediated [ combined with these TKIs. In contrast, EGFR and VEGFR antibodies cetuximab and bevacizumab had no effect on [ between nucleoside drugs and TKIs that may reduce treatment efficacy when these agents are administered together.
In combination toxicity studies, cells showed greater sensitivity to drug combinations when cells were exposed to gemcitabine for 24 hours followed by erlotinib, gefitinib or vandetanib as predicted from our uptake inhibition studies. There were mostly additive to antagonistic interactions if the TKI was added first followed by gemcitabine or simultaneously with the exception of vandetanib in A549 and AsPC-1 in simultaneous addition. Synergism observed in the sequential schedule of nucleoside drug followed by TKIs is supported by results from a recent phase III trial (FASTACT-2) (35), wherein untreated stage IIIB/IV NSCLC patients were randomized and treated with gemcitabine plus platinum followed by intercalated erlotinib or placebo every 4 weeks. Treatment with intercalated combination of erlotinib and chemotherapy improved PFS vs. chemotherapy alone as first-line treatment in patients with advanced NSCLC with known and unknown EGFR mutation status.
Although it is difficult to extrapolate in vitro studies to the clinic especially with drugs that have such extensive protein binding and accumulation in tumors, concentrations of erlotinib, gefitinib or vandetanib achievable in plasma are levels that would inhibit hNT activity and tumor levels are at least 40 fold higher than plasma levels. In a recent study of neoadjuvant breast cancer patients, mean gefitinib plasma concentrations at steady state were 0.18 µg/mL (0.403 µM) and mean tumor levels were 7.5 µg/g (17 µM), approximately 42 fold higher (36). In two related studies median plasma gefitinib levels were 1064 ng/ml on day 8 (37) and tumor levels were shown to be approximately 40 fold higher than plasma levels (22.7 versus 0.52 µM) (38).
In a phase I study at the 300 mg/day dose of vandetanib, steady state mean vandetanib concentrations were approximately 1000 ng/ml (2.1 µM) (13) . Vandetanib administered at doses 
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